OverviewSuggest Edit

Synlogic is a biopharmaceutical company that focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases. The Company was formed as a result of a reverse merger between Mirna Therapeutics and Synlogic. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The Сompany is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors.

TypePublic
Founded2013
HQCambridge, MA, US
Websitesynlogictx.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Mar 2019)74(+18%)
Job Openings11
Revenue (FY, 2020)$545 K(-75%)
Share Price (Nov 2021)$2.8(+5%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Synlogic

Peter Barrett

Peter Barrett

Chairman
Aoife M. Brennan

Aoife M. Brennan

President, Chief Executive Officer & Director
Gregg Beloff

Gregg Beloff

Interim Chief Financial Officer
Mike Burgess

Mike Burgess

Director
Richard Riese

Richard Riese

Chief Medical Officer
Ed Mathers

Ed Mathers

Director
Show more

Synlogic Office Locations

Synlogic has an office in Cambridge
Cambridge, MA, US (HQ)
301 Binney St #402Cambridge
Show all (1)

Synlogic Financials and Metrics

Synlogic Revenue

Synlogic's revenue was reported to be $545 k in FY, 2020
USD

Net income (Q1, 2021)

(15.0m)

EBIT (Q1, 2021)

(15.0m)

Market capitalization (12-Nov-2021)

138.8m

Closing stock price (12-Nov-2021)

2.8

Cash (31-Mar-2021)

26.7m

EV

134.3m
Synlogic's current market capitalization is $138.8 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

2.4m2.5m2.2m545.0k

General and administrative expense

6.1m8.1m12.9m15.7m14.7m13.5m

R&D expense

18.9m13.9m30.3m38.0m41.9m47.5m

Operating expense total

25.0m26.5m43.3m53.8m56.6m61.0m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

111.0k354.0k254.0k1.8m338.0k350.0k305.0k100.0k445.0k

General and administrative expense

1.6m2.1m2.0m1.9m2.3m4.2m3.2m3.6m4.7m3.4m3.7m3.7m3.9m3.8m3.5m3.0m3.9m

R&D expense

4.7m4.5m3.7m3.4m242.0k5.1m9.0m8.4m10.9m9.9m10.4m9.7m10.6m12.7m12.9m10.5m11.2m

Operating expense total

6.2m6.7m5.7m5.3m5.1m9.5m12.2m12.0m15.6m13.3m14.0m13.4m14.4m16.5m16.4m13.4m15.0m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

89.7m16.4m58.4m11.3m26.2m32.5m

Prepaid Expenses

1.6m1.6m13.7m6.4m

Inventories

793.0k882.0k

Current Assets

90.5m61.4m88.6m124.3m133.2m106.8m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

35.7m52.9m30.8m27.0m17.1m15.2m79.2m27.2m26.6m17.3m15.7m17.4m27.5m19.5m31.4m26.8m26.7m

Accounts Receivable

2.0m2.5m

Prepaid Expenses

303.0k818.0k620.0k387.0k1.7m2.1m2.1m1.4m1.5m31.4m10.5m13.2m13.1m8.7m6.8m

Current Assets

36.1m81.6m73.5m67.1m58.1m48.1m98.2m127.9m145.3m136.0m113.8m162.9m131.3m127.4m122.2m110.6m101.2m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(25.0m)(26.3m)(40.4m)(48.4m)(51.4m)(59.2m)

Depreciation and Amortization

54.0k159.0k2.3m2.4m2.7m2.6m

Inventories

793.0k107.0k

Accounts Payable

3.7m(3.3m)4.1m(257.0k)(935.0k)(349.0k)
USDQ3, 2015

Financial Leverage

-0.6 x
Show all financial metrics

Synlogic Operating Metrics

FY, 2016

Patents Issued

10

Patents Pending

42
Show all operating metrics

Synlogic Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Synlogic Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Synlogic Online and Social Media Presence

Embed Graph

Synlogic News and Updates

Synlogic Reports Third Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the third quarter ended September 30, 2021 and provided an update on...

Synlogic Announces Presentation of Phenylketonuria Data at 14th International Congress of Inborn Errors of Metabolism Meeting

CAMBRIDGE, Mass., Nov. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced presentation of new data from the company's clinical development program for phenylketonuria...

Synlogic Announces Nature Communications Publication Highlighting Use of Synthetic Biotic Platform to Optimize Therapies for Phenylketonuria

CAMBRIDGE, Mass., Oct. 28, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced a publication in Nature Communications documenting the engineering of a more potent phenylalanine...

Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021

CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at the upcoming American Society for Nephrology (ASN) Kidney Week 2021,...

Synlogic Appoints Molly Harper as Chief Business Officer

CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Molly Harper as Chief Business Officer. Ms. Harper will provide strategic...

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria

CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational...
Show more

Synlogic Frequently Asked Questions

  • When was Synlogic founded?

    Synlogic was founded in 2013.

  • Who are Synlogic key executives?

    Synlogic's key executives are Peter Barrett, Aoife M. Brennan and Gregg Beloff.

  • How many employees does Synlogic have?

    Synlogic has 74 employees.

  • What is Synlogic revenue?

    Latest Synlogic annual revenue is $545 k.

  • What is Synlogic revenue per employee?

    Latest Synlogic revenue per employee is $7.4 k.

  • Who are Synlogic competitors?

    Competitors of Synlogic include Pandion Therapeutics, Jnana and ImCheck Therapeutics.

  • Where is Synlogic headquarters?

    Synlogic headquarters is located at 301 Binney St #402Cambridge, Cambridge.

  • Where are Synlogic offices?

    Synlogic has an office in Cambridge.

  • How many offices does Synlogic have?

    Synlogic has 1 office.